Form 4: Regulus Therapeutics CFO Crispin Calzada Acquires Shares Through RSU Vesting

Regulus Therapeutics' Chief Financial Officer, Crispin Calzada, acquired shares of common stock through the vesting of previously granted Restricted Stock Units (RSUs).

Summary

• Crispin Calzada, the Chief Financial Officer of Regulus Therapeutics, acquired 62,500 shares of common stock at $1.36 per share and 21,000 shares at $1.30 per share on January 9, 2025.
• These acquisitions resulted from the vesting of Restricted Stock Units (RSUs) that were granted on August 10, 2023 and January 12, 2024.
• The RSUs vested upon the achievement of specific performance-based milestones, with 50% vesting immediately upon milestone achievement and the remaining 50% vesting one year later, contingent on continuous service.

Sentiment

Score: 7

Explanation: The document reflects a positive event (vesting of RSUs due to performance milestones) and insider confidence (CFO acquiring shares), but it is a routine filing and not a major catalyst.

Positives

• The vesting of RSUs indicates that performance milestones were met, which is a positive sign for the company.
• The acquisition of shares by the CFO demonstrates confidence in the company's future prospects.

Future Outlook

The remaining 50% of the RSUs granted on August 10, 2023 and January 12, 2024 will vest on the one-year anniversary of the vesting commencement date, subject to the reporting person's continuous service.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders acquire or dispose of company stock. It reflects the compensation structure of the company and the alignment of management's interests with shareholders.

Comparison to Industry Standards

• The vesting of RSUs based on performance milestones is a common practice in the biotechnology industry, aligning executive compensation with company performance.
• Many biotech companies use RSUs as part of their compensation packages to attract and retain talent, similar to Regulus Therapeutics.
• The vesting schedule of 50% immediately upon milestone achievement and the remaining 50% after one year is also a typical vesting structure.

Stakeholder Impact

• Shareholders may view the vesting of RSUs and subsequent share acquisition by the CFO as a positive sign, indicating that performance goals are being met and management is aligned with their interests.
• Employees may see this as a positive sign of company performance and stability.

Next Steps

• The remaining 50% of the RSUs will vest on the one-year anniversary of the vesting commencement date, subject to the reporting person's continuous service.

Key Dates

Keywords

Regulus Therapeutics, RGLS, CFO, Crispin Calzada, Restricted Stock Units, RSU, Share Acquisition, Vesting, Performance Milestone, Insider Trading